Why Is Electroconvulsive Therapy Still Underused?: April 2019

3.00 CME
180 MINS
$30 FEE
SAVE
Psych Annals April 2019 Cover

Overview

Table of Contents

Does Electroconvulsive Therapy Injure the Brain?

Stephen H. Dinwiddie, MD

The Cognitive Effects of Electroconvulsive Therapy: A Critical Review

Caterina Mosti, PhD; and Michael Brook, PhD

Uses of Electroconvulsive Therapy in Conditions Other than Major Depressive Episode

Sandarsh Surya, MBBS; Ram Bishnoi, MBBS, MD; Peter B. Rosenquist, MD; and William V. McCall, MD, MS

Continuation Therapies After Successful Treatment with Electroconvulsive Therapy in Major Depressive Disorder

Brendan J. O’Connor, MD; and Charles R. Conway, MD


Sponsorship Statement

This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals.


Support Statement

There is no commercial support for this activity.


Learning Objectives

1. Recognize recent studies on the effect of electroconvulsive therapy on brain structure.

2. Describe the cognitive changes associated with ECT, as well as the various moderating factors contributing to the heterogeneity in cognitive findings.

3. Describe how to manage patients with major depressive disorder after remission with electroconvulsive therapy.

4. Recognize the efficacy of electroconvulsive therapy in the treatment of neuropsychiatric conditions other than major depressive illness.

Faculty names and affiliations:  See authors above

Guest Editor: Stephen H. Dinwiddie, MD

Reviewer names:  Andrew A. Nierenberg, MD, Editor and Lenard A. Adler, MD, CME Coordinator, Psychiatric Annals


Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue and also on this page.

Faculty members report the following financial relationships:   Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly and Company; EpiQ, Forest; Johnson and Johnson; Labopharm; Merck; Methylation Science; Novartis; PamLabs; PGx Health; Shire; Schering-Plough; Sunovion; Takeda/Lundbeck Pharmaceuticals; Targacept; Teva: Consultant. APSARD; Belvoir Publishing; Boston Center for the Arts; University of Texas Southwestern Dallas; Hillside Hospital; American Drug Utilization Review; American Society for Clinical Psychopharmacology; Bayamon Region Psychiatric Society; Baystate Medical Center; Canadian Psychiatric Association; Columbia University; Douglas Hospital/McGill University; IMEDEX; International Society for Bipolar Disorders; Israel Society for Biological Psychiatry; John Hopkins University; MJ Consulting; Massachusetts Association of College Counselors; Medscape; MBL Publishing; Physicians Postgraduate Press; Ryan Licht Sang Foundation; Slack Publishing; SUNY Buffalo; University of Florida; University of Miami; University of Wisconsin; University of Pisa; SciMed: Honoraria / travel expenses. Appliance Computing, Inc.; Brain Cells, Inc.: Stock options. AHRQ; Cephalon; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals; Takeda; Elan; Shire: Grant / research support.
Lenard A. Adler has disclosed the following relevant financial relationships: research grants paid to New York University (NYU) on Dr. Adler’s behalf from Sunovion Pharmaceuticals, Shire Pharmaceuticals, Lundbeck, Enzymotec, Purdue Pharma; personal fees for consulting or advisory boards from Sunovion Pharmaceuticals, Enzymotec, Shire Pharmaceuticals, the National Football League, Major League Baseball, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Alcobra Pharmaceuticals; and royalty fees from NYU School of Medicine for license of Adult ADHD rating scales and training materials

Authors report the following financial relationships: Stephen H. Dinwiddie has no relevant financial relationships to disclose. Caterina Mosti has no relevant financial relationships to disclose. Michael Brook has no relevant financial relationships to disclose. Sandarsh Surya has no relevant financial relationships to disclose. Ram Bishnoi has no relevant financial relationships to disclose. Peter B. Rosenquist has no relevant financial relationships to disclose. William V. McCall is on the speakers bureau of CME Outfitters, a consultant for Sage Therapeutics, has performed contracted research for MECTA Corporation and Merck & Co., and receives royalties from Wolters Kluwer Publishing. Brendan J. O’Connor has no relevant financial relationships to disclose. Charles R. Conway has received consulting fees and honoraria from LivaNova.


Accreditation statement(s)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and SLACK Incorporated. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Release date:  April 1, 2019. Expiration Date:  May 1, 2022.


How to Participate

To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, AKH Inc., Advancing Knowledge in Healthcare will issue an AMA PRA Category 1 Credit(s)™ certificate.


Target Audience

This CME activity is primarily targeted to patient-caring psychiatrists, physicians specializing in psychiatry and others allied to the field. There are no specific background requirements for participants taking this activity. Learning objectives and author disclosures are found at the beginning of each CME article.


Unlabeled and Investigational Usage Statement

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.


Copyright Statement

Copyright © 2019 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.